Literature DB >> 7089561

The anticancer agent adriamycin can be actively cytotoxic without entering cells.

T R Triton, G Yee.   

Abstract

The antineoplastic agent adriamycin was coupled to an insoluble agarose support. This material was actively cytotoxic to L1210 cells in culture under conditions in which no free adriamycin could enter the cell. It is concluded that an agent whose principal target was previously thought to be DNA can exert its cytotoxic action solely by interaction at the cell surface.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7089561     DOI: 10.1126/science.7089561

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  109 in total

1.  Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity.

Authors:  Azadeh Kheirolomoom; Lisa M Mahakian; Chun-Yen Lai; Heather A Lindfors; Jai Woong Seo; Eric E Paoli; Katherine D Watson; Eric M Haynam; Elizabeth S Ingham; Li Xing; R Holland Cheng; Alexander D Borowsky; Robert D Cardiff; Katherine W Ferrara
Journal:  Mol Pharm       Date:  2010-12-06       Impact factor: 4.939

2.  Individuation of subcellular targets of antitumor agents by ultrastructural methods.

Authors:  G Arancia
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

3.  Activity of doxorubicin covalently bound to a novel human serum albumin microcapsule.

Authors:  M Eatock; N Church; R Harris; W Angerson; C McArdle; R French; C Twelves
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 4.  The human tumor colony-forming chemosensitivity assay: a biological and clinical review.

Authors:  E C Bradley; B F Issell; R Hellman
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

Review 5.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

6.  Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage?

Authors:  R E Durand
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  Predictive tests in cancer chemotherapy. A reappraisal.

Authors:  R Osieka; S Seeber; C G Schmidt
Journal:  Klin Wochenschr       Date:  1984-03-01

8.  Anthracycline-binding induced DNA stiffening, bending and elongation; stereochemical implications from viscometric investigations.

Authors:  K E Reinert
Journal:  Nucleic Acids Res       Date:  1983-05-25       Impact factor: 16.971

9.  Inhibition of Epstein-Barr-virus-transformed human chronic lymphocytic leukaemic B cells with monoclonal-antibody-adriamycin (doxorubicin) conjugates.

Authors:  Z Zhu; J Kralovec; T Ghose; M Mammen
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

10.  Survival of rat mammary tumor cell clones and DNA strand damage following adriamycin treatment.

Authors:  D P Evans; R E Meyn; S P Tomasovic
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.